VP of Research - AIQ Solutions
Joined June 2015
- Tweets54
- Following35
- Followers30
- Likes274
Timothy Perk retweeted
Eligibility for PSMA-RLT based on dual FDG/PSMA-PET: a subanalysis of the #3TMPO study. Presentation by Jean-Mathieu Beauregard @chudequebec. #SNMMI24 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4aTpkzj @SNM_MI
Timothy Perk retweeted
Congratulations to the @wiscmedphys @UWSMPH researchers awarded patents in March: Daniel Huff & Robert Jeraj!
Tell us your idea: warf.org/disclose
See the patent: ppubs.uspto.gov/dirsearch-pu…
Timothy Perk retweeted
Dr. Robert Jeraj, AIQ CSO and faculty member of the @UWMadison , will be a featured speaker on Course 5 of @sitcancer and @thenci Computational Immuno-oncology Webinar Series, moderated by Dr. Matthew Reilley. Register today! sitc.execinc.com/edibo/NCI23…
#immunotherapy #immunooncology #webinar
Timothy Perk retweeted
1/ Excited to share our latest paper! 🧵
Performance of an automated registration-based method for longitudinal lesion matching and comparison to inter-reader variability doi.org/10.1088/1361-6560/ac… via @ioppublishing
Timothy Perk retweeted
We are getting excited to be at #SNMMI2023 next weekend in Chicago. Please reach out today to schedule a time to meet with us at Booth 8053. aiq-solutions.com
Timothy Perk retweeted
We have a fantastic team of rising ⭐️s @EliasChandran @GMIannantuonoMD @NicholasISimon @NCIResearchCtr presenting our #BladderCancer posters on 1]mismatch repair deficiency & MSI 2]Olaparib biomarker-selected TPS 3]M7824 +NHS-IL12 +/-XRT study 4] AI with PET/CT @ASCO #ASCO23
It is great to be between two young rising stars in GU oncology working at @nciccr_gmb 🔥🔝
@EliasChandran @NicholasISimon
#ASCO2023
Timothy Perk retweeted
We are at #ASCO23 and we have a booth and a kiosk - two times the reasons to stop by and say hi! Visit our #booth 18045 to learn more about our Hospital Early Access Program or come by our #kiosk IH23 in the Innovation Hub to learn more about our clinical research applications for therapy and tracer development. We look forward to seeing you! Click here to learn more aiq-solutions.com.
Timothy Perk retweeted
We are at @ASCO #GU23 today and tomorrow! Meet us at Poster Session B: Prostate Cancer and Urothelial Carcinoma, Friday, Feb 17, 12:30pm PT or stop by Booth 39 to learn more about TRAQinform IQ technology. #ai #technology
Timothy Perk retweeted
Learn about the future of oncology and therapy: ow.ly/5BcK50Mogfc
#MolecularImaging and #Theranostics = Precision Oncology
#Cancer #NuclearMedicine #JNuclMed
Timothy Perk retweeted
Imaging adaptive immune responses to immunotherapies to improve outcomes. ow.ly/Lfjy50LZtxC
#MolecularImaging = #PrecisionOncology
#NuclearMedicine #Cancer @UABRadiology
Timothy Perk retweeted
This week Thursday! Join our Imaging Innovations #webinar with distinguished professor and #amyloidosis expert Dr. Jonathan Wall of @utgsm and our own @aj_weisman to hear the latest on #AI imaging. Register for free: buff.ly/3EGfioz
Timothy Perk retweeted
And he just received a Best Poster Award!! Congratulations Andrew Sedlack @ajhsedlack!!
Timothy Perk retweeted
Targeted alpha therapy with ²¹²Pb-DOTAMTATE in #NETcancer patients has shown great potential, exceeding the standard-of-care treatments currently available; Phase II study coming soon! ow.ly/Qstx50KB6eK @delpassand
#Theranostics = #PrecisionOncology
Timothy Perk retweeted
Today Novartis announced it will suspend production of Lutathera and Pluvicto at its radioligand therapy production sites in Ivrea, Italy, and Milburn, New Jersey, temporarily affecting commercial and clinical trial supply. ow.ly/BSeN30sj0OB #NuclearMedicine #PETCT #RPT
Timothy Perk retweeted
Webinar: How targeted #radiotherapy induced #toxicity can be identified with imaging
Join @PharmaIQ & @aiq_solutions this Thursday to learn how #AI assisted analysis of radiological scans enhances understanding of treatment efficacy
▶ Register now: ow.ly/P3EA50ISHI2
